Erin Wilson
Stock Analyst at Morgan Stanley
(1.76)
# 3,352
Out of 5,141 analysts
23
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $28 → $22 | $6.57 | +234.86% | 8 | Sep 2, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $190.02 | +285.22% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $168.92 | +127.92% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $165.62 | +60.00% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $453.77 | -54.82% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $99.70 | +150.75% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $24.98 | +52.12% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $23.18 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $510.93 | -33.26% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $0.88 | +6,036.36% | 4 | Nov 14, 2017 |
Rapid7
Sep 2, 2025
Maintains: Equal-Weight
Price Target: $28 → $22
Current: $6.57
Upside: +234.86%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $190.02
Upside: +285.22%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $168.92
Upside: +127.92%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $165.62
Upside: +60.00%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $453.77
Upside: -54.82%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $99.70
Upside: +150.75%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $24.98
Upside: +52.12%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $23.18
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $510.93
Upside: -33.26%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $0.88
Upside: +6,036.36%